- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about ESALF
Recent news which mentions ESALF
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
January 24, 2025
From Benzinga
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
August 22, 2024
From Benzinga
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
July 26, 2024
From Benzinga
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
From Benzinga
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
From Benzinga
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
June 11, 2024
From Benzinga
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
From Benzinga
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
From Benzinga
Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment
November 08, 2023
From MarketWatch
Eli Lilly chief scientific officer ‘extremely optimistic’ that major new Alzheimer’s breakthrough is coming
November 06, 2023
From MarketWatch
From MarketWatch
From MarketWatch
From Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
From Benzinga
From Benzinga
From Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
September 22, 2023
From Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
August 25, 2023
From Benzinga
Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer’s disease
July 31, 2023
From MarketWatch
From MarketWatch
From MarketWatch
Eli Lilly’s Alzheimer’s treatment shows promise in early stages of disease — but safety concerns remain
July 17, 2023
From MarketWatch
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
From Benzinga
Biogen’s big Alzheimer’s drug win fails to boost the stock as analysts see slow Leqembi rollout
July 07, 2023
From MarketWatch
From MarketWatch
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
From Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
From Benzinga
Goldman pushes back against bearish Morgan Stanley’s Mike Wilson with new 4,500 S&P 500 target
June 12, 2023
From MarketWatch
Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move
June 12, 2023
From MarketWatch
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.